Form 8-K Vir Biotechnology, Inc. For: Jun 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vir Biotechnology (VIR) PT Raised to $15 at Morgan Stanley
June 5, 2024 2:37 PM EDTMorgan Stanley analyst Michael Ulz raised the price target on Vir Biotechnology (NASDAQ: VIR) to $15.00 (from $12.00) while maintaining a Equalweight rating.
The analyst comments "Updated, preliminary results from the Ph2 SOLSTICE study in hepatitis delta (HDV) confirm robust and durable antiviral activity, while... More
